@article{ATM33943,
author = {Claudia Marchetti and Andrea Rosati and Giovanni Scambia and Anna Fagotti},
title = {Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 8},
year = {2019},
keywords = {},
abstract = {Despite initial maximal surgical effort and successful response to medical treatment, recurrence is a common event in high-grade serous ovarian cancer (HGSOC), with 75% of women experiencing relapse within 2 years from diagnosis (1). At relapse, patients with platinum sensitive recurrent ovarian cancer (PSROC) are frequently retreated with platinum-based doublets (2). Furthermore, maintenance therapy should be offered, either with bevacizumab, or with Parp-inhibitors (PARPi) (3-5), if not previously administrated.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/33943}
}